New Zealand - English - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - conjugated estrogens 1.25mg;   - tablet - 1.25 mg - active: conjugated estrogens 1.25mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate ink lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose quinoline yellow shellac stearic acid sucrose sunset yellow fcf titanium dioxide

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - medroxyprogesterone acetate; conjugated oestrogens - oral tablet - 10mg ; 625microgram

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, conjugated 0.625 mg - esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. should not be used in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of cancer of the breast. 3. known or suspected estrogen-dependent neoplasia. 4. active deep vein thrombosis, pulmonary embolism or history of these conditions. 5. active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). 6. liver dysfunction or disease. 7. esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. should not be used in patients with known hypersensitivity to its ingredients. 8. known or suspected pregnancy. there is no indication for esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions . ) methyltestosterone should not be used in: 1. the presence of severe liver damage. 2. pregnancy and in breast-feeding mothers because of the possibility of masculinization of the female fetus or breast-fed infant.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; norgestrel - coated tablet - 0.625 milligram(s) - progestogens and estrogens, sequential preparations; norgestrel and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; norgestrel - coated tablet - 1.25 milligram(s) - progestogens and estrogens, sequential preparations; norgestrel and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; medroxyprogesterone acetate - coated tablet - 0.625 mg/2.5 milligram(s) - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens; medroxyprogesterone acetate - coated tablet - 0.625mg/5m percent volume/volume - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 0.625 milligram - natural and semisynthetic estrogens, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - estrogens conjugated - tablet prolonged release - 1.25 milligram - natural and semisynthetic estrogens, plain

Canada - English - Health Canada

pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 2.5mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 2.5mg - estrogens